Lv11
10 积分 2025-12-09 加入
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer
1小时前
已完结
Lorlatinib vs crizotinib as first-line treatment for advancedALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study
1小时前
已完结
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
1小时前
已完结
The Glycosyltransferase XYLT1 Activates NF-κB Signaling to Promote Metastasis of Early-Stage Lung Adenocarcinoma
6个月前
已完结
皖公网安备34019202002308
